Global Scleroderma Market Size, Status and Forecast 2025

2018-05-24 13:50:16

According to new report published by Reports Monitor titled, “Global Scleroderma Market for by Drug, indication, Mode of Test Type: Global Opportunity Analysis and Industry Forecast 2017-2025,” the scleroderma market was valued at XX million in 2016, and is projected to reach at XX million by 2025, growing at CAGR of XX% from 2017 to 2025.


According to Scleroderma Organisation, there are around 300,000 Americans who have scleroderma. There are around one third of those people who are suffering from systemic form of scleroderma.  Since, it is difficult to predict the symptoms of scleroderma therefore; there may be some cases which can be misdiagnosed or undiagnosed.  It is estimated that localized scleroderma is mostly found in children while systemic scleroderma is found in adults. Also, according to research & development in the field of scleroderma, there is more number of females who are suffering from scleroderma than men. Scleroderma can be seen in any of the age group between the ages of 25 to 55.


On the basis of drugs, market is segmented into Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, Prostacyclin Analogues and others. On the basis of indication, market is segmented into localized and systematic. On the basis of mode of test type, market is segmented into skin biopsy, imaging techniques, blood tests, pulmonary function tests, electrocardiogram and echocardiogram.


                                                Know More| Request for Sample PDF Brochure


Rising number of patients of scleroderma and rising prevalence of genetic mutations are the major drivers that are fuelling the growth in the scleroderma market. However, high cost of drugs and additional cost due to research & development of drugs are the main factors that may impede the growth of the market. On the other hand, the introduction of new medical solutions and high unmet medical needs associated with scleroderma are the important factors that have created future growth opportunities.


Geographically, the global scleroderma market can be analysed into North America, Asia-Pacific, Europe and LAMEA.  Better diagnostic treatment available, proactive awareness due to several foundations associated with healthcare disease are the factors that have driven the growth of the market in North America and Europe.  In addition, presence of prominent pharmaceutical companies, medical institutes in the developing countries and research organisation are emphasized on finding a standard treatment. Moreover, Asia Pacific market is driven factors such as emerging economies, high adoption of new therapies at reasonable costs are the important factor that has an Competitive Landscape.


Major key players in the market are Actelion Pharmaceuticals, Inc, Bayer AG, Corbus Pharmaceutical Holdings Inc., Boehringer Ingelheim, Cytori Therapeutics, Inc., Pfizer, Inc., Sanofi, Cumberland Pharmaceuticals, Inc.  and Gilead Sciences, Inc.


About Garner Insights:

We at Garner Insights.com provide a comprehensive analysis by providing in-depth reports of the various market verticals. Our Mission is to provide a detailed analysis of the vast markets worldwide backed by rich data. Decision makers can now rely on our well-defined data gathering methods to get the correct and accurate market forecasting along with detailed analysis.


Contact Us:

Kevin Thomas

Direct:

+1 513 549 5911 (US)

+44 203 318 2846 (UK)

Email: [email protected]

Related Press Releases